The following table highlights the drugs which are expected to come off patent over the next three years.
Drugs initiated mainly in primary care have been listed and many of the anti-neoplastic and monoclonal antibody drugs have not been included as they are mainly hospital-only.
|Generic Name||Brand Name||Patent expiry Month|
|Simvastatin + Ezetimibe||Inegy||April|
|Beclometasone diproionate + formoterol fumarate||Fostair||Jul|
|Dienogest + estradiol valerate (Qlaira®)||Qlaira||Oct|
|Amlodipine + valsartan||Exforge||Dec|
Expiry dates in the table above take account of any patent extensions afforded by a Supplementary Protection Certificate (SPC) and a paediatric investigation plan, which together can extend a product’s patent – and protection from generic competition – by up to five and a half years.
The table also indicates where a licence for a generic product is in the latter stages of the EU licensing process, or is already available in the EU. However, it does not follow that a generic product will be available in the UK as patent issues vary between countries. Patent legislation is complex and the above table is for guidance only.
Please also note that expected patent expiry dates are subject to change when new extensions (SPC or paediatric) are granted or if a legal decision alters the patent status of a drug. In addition, the expiries listed here only cover the basic manufacturing patent; additional patents on formulations and uses can influence when a generic becomes available commercially.
The DDA cannot be held responsible for any losses resulting from inaccuracies in this table.